NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $113 million in its third quarter.
The Novato, California-based company said it had a loss of $1.96 per share.
The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.71 per share.
The biotechnology company posted revenue of $25.8 million in the period, also falling short of Street forecasts. Eight analysts surveyed by Zacks expected $28.6 million.
Ultragenyx shares have declined slightly more than 8% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $39.86, a decline of 25% in the last 12 months.